Tags

Type your tag names separated by a space and hit enter

Review article: diagnosis and treatment of non-alcoholic fatty liver disease.
Aliment Pharmacol Ther. 2008 Sep 01; 28(5):503-22.AP

Abstract

BACKGROUND

Non-alcoholic fatty liver disease (NAFLD) is an increasingly prevalent condition affecting adults and children, leading to significant morbidity. It is often associated with the metabolic syndrome, although multiple pathogenetic mechanisms have been suggested. In the coming decades, it promises to be the leading cause of liver disease in industrial countries.

AIM

To provide a comprehensive, updated review of diagnosis and management of NAFLD and to appraise the evolution of new modalities in these areas.

METHODS

An Ovid MEDLINE search was performed to identify pertinent original research and review articles. Selected references in these articles were also evaluated.

RESULTS

The diagnosis of hepatic steatosis and steatohepatitis or non-alcoholic steatohepatitis (NASH) is not yet possible without liver biopsy. This is impractical given the large numbers affected by the condition. Current therapy has focused on improving insulin resistance and mediators of inflammation, factors probably associated with disease progression.

CONCLUSIONS

There are no proven non-invasive diagnostic modalities to distinguish NAFLD and NASH, but new biomarker panels are approximating the liver biopsy in accuracy. Therapeutic targets of drug development are in early stages, but a multifaceted approach will probably yield several treatment options in the years to come.

Authors+Show Affiliations

Cedars Sinai Medical Center, Los Angeles, CA, USA.No affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Review

Language

eng

PubMed ID

18532991

Citation

Oh, M K., et al. "Review Article: Diagnosis and Treatment of Non-alcoholic Fatty Liver Disease." Alimentary Pharmacology & Therapeutics, vol. 28, no. 5, 2008, pp. 503-22.
Oh MK, Winn J, Poordad F. Review article: diagnosis and treatment of non-alcoholic fatty liver disease. Aliment Pharmacol Ther. 2008;28(5):503-22.
Oh, M. K., Winn, J., & Poordad, F. (2008). Review article: diagnosis and treatment of non-alcoholic fatty liver disease. Alimentary Pharmacology & Therapeutics, 28(5), 503-22. https://doi.org/10.1111/j.1365-2036.2008.03752.x
Oh MK, Winn J, Poordad F. Review Article: Diagnosis and Treatment of Non-alcoholic Fatty Liver Disease. Aliment Pharmacol Ther. 2008 Sep 1;28(5):503-22. PubMed PMID: 18532991.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Review article: diagnosis and treatment of non-alcoholic fatty liver disease. AU - Oh,M K, AU - Winn,J, AU - Poordad,F, Y1 - 2008/06/03/ PY - 2008/6/6/pubmed PY - 2008/9/25/medline PY - 2008/6/6/entrez SP - 503 EP - 22 JF - Alimentary pharmacology & therapeutics JO - Aliment. Pharmacol. Ther. VL - 28 IS - 5 N2 - BACKGROUND: Non-alcoholic fatty liver disease (NAFLD) is an increasingly prevalent condition affecting adults and children, leading to significant morbidity. It is often associated with the metabolic syndrome, although multiple pathogenetic mechanisms have been suggested. In the coming decades, it promises to be the leading cause of liver disease in industrial countries. AIM: To provide a comprehensive, updated review of diagnosis and management of NAFLD and to appraise the evolution of new modalities in these areas. METHODS: An Ovid MEDLINE search was performed to identify pertinent original research and review articles. Selected references in these articles were also evaluated. RESULTS: The diagnosis of hepatic steatosis and steatohepatitis or non-alcoholic steatohepatitis (NASH) is not yet possible without liver biopsy. This is impractical given the large numbers affected by the condition. Current therapy has focused on improving insulin resistance and mediators of inflammation, factors probably associated with disease progression. CONCLUSIONS: There are no proven non-invasive diagnostic modalities to distinguish NAFLD and NASH, but new biomarker panels are approximating the liver biopsy in accuracy. Therapeutic targets of drug development are in early stages, but a multifaceted approach will probably yield several treatment options in the years to come. SN - 1365-2036 UR - https://www.unboundmedicine.com/medline/citation/18532991/Review_article:_diagnosis_and_treatment_of_non_alcoholic_fatty_liver_disease_ L2 - https://doi.org/10.1111/j.1365-2036.2008.03752.x DB - PRIME DP - Unbound Medicine ER -